Site-Specific, Efficient, Large–Cargo Targeting
Site-Specific, Efficient, Large-Cargo Targeting, or Sselect™, is a gene insertion technology that enables large DNA fragment insertion at a safe harbor locus in human cells. Sselect™ uses integrase PhiC31 variants identified through directed evolution approach. This technology recognizes and inserts large cargo DNA at a human safe harbor locus. Sselect™ is applicable to both allogeneic and autologous cell therapy development, as well as in vivo gene therapy modality.
Spotlight on Sselect™
Sselect™ gene insertion technology has the following key features:
- PhiC31 integrase variants
- Direct evolution approach for exclusively mammalian cells
- One-fusion protein for PhiC31 integrase variants and linker-dMAD7
- Simple, one-step gene insertion
- Single target genomic safe harbor locus
Interested in Becoming a SSELECT Sselect™ Partner?
We are looking for partners in the continued development of SSELECT Sselect™ technology.
ASC’s IP for Sselect™
Key claims:
- PhiC31 integrase variants
- Directed evolutions method in mammalian cells (vs. bacterial cells)
- One fusion protein (phiC31 variants-linker-dMAD7)
- One-step gene insertion (simple)
- Target one genomic safe harbor locus
8023, Methods for screening variant of target gene
Granted (November 8, 2022)(exp Febraury 8, 2039)
8032, Integrase variants for gene insertion in human cell
Provisional filed February 2022; PCT filed February 7, 2023
Services
Catalog ID# | Service Name | Price | |
---|---|---|---|
|